Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Phase 2
Not yet recruiting
- Conditions
- Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT07016230
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 162
- Registration Number
- NCT07001618
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
Not Applicable
Not yet recruiting
- Conditions
- Ototoxicity, Drug-InducedOtotoxicity, Radiation-InducedPediatric Cancer
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 500
- Registration Number
- NCT06957132
- Locations
- 🇫🇷
Hôpital Necker, Paris, France
🇫🇷Institut Curie, Paris, France
🇫🇷Gustave Roussy, Villejuif, France
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Phase 4
Not yet recruiting
- Conditions
- Kidney CancerRenal Cell Cancer
- Interventions
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT06934057
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - Angers, Angers, France
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷Centre Léon Bérard, Lyon, France
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
Not Applicable
Not yet recruiting
- Conditions
- Risk of Breast CancerRisk of Colorectal CancerRisk of Upper Gastrointestinal CancersRisk of Hepatic CancersRisk of Lung CancerRisk of Skin Cancers Except Basal-cell CarcinomasRisk of Head and Neck CancersRisk of MesotheliomaRisk of Gynaecological CancerRisk of Kidney Cancer
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 5909
- Registration Number
- NCT06907095
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Study on the Effectiveness and Comfort of Innovative Solutions for the Internal Transport of Patients in Wheelchairs in a Hospital Setting
Phase 2
Recruiting
- Conditions
- Hospitalized Patient
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 154
- Registration Number
- NCT06902883
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
Phase 3
Recruiting
- Conditions
- Oligometastatic Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Radiation: Radical local treatmentDrug: SoC-based immunotherapy (+/- chemotherapy)
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 124
- Registration Number
- NCT06840782
- Locations
- 🇫🇷
Institut de Radiothérapie du Sud de l'Oise, Creil, Hauts-de-France, France
🇫🇷Centre Sainte-Catherine, Avignon, Provence-Alpes-Côte d'Azur, France
🇫🇷Gustave Roussy, Villejuif, Île-de-France, France
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
Not Applicable
Recruiting
- Conditions
- Diffuse Large B-Cell LymphomaFollicular Lymphoma
- Interventions
- Biological: blood sampling
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT06813573
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIHR+ Breast CancerAI-related Musculoskeletal Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 130
- Registration Number
- NCT06787118
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 180
- Registration Number
- NCT06781996
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France